Morgan Stanley on Amgen (AMGN): 'Initial thoughts on Maritide Ph2 diabesity data'
Tweet Send to a Friend
Morgan Stanley analyst Terance Flynn reiterated an Equalweight rating and $22.00 price target on Amgen (NASDAQ: AMGN)The analyst comments "AMGN ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
